What this pack is
Tylenol Extra Strength is the brand name in this record; acetaminophen is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
Tylenol Extra StrengthGeneric nameacetaminophen
How this medicine works
This page only identifies the product as an OTC analgesic and fever reducer containing acetaminophen; it does not turn a category description into personal suitability, tablet count, interval or duration.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Tylenol Extra Strength
- Generic name
- acetaminophen
- Dosage-form class
- Oral film-coated caplets: acetaminophen 500 mg per caplet; this dossier displays exact package NDC 50580-937-50
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v16; effective 22 Jul 2026 and published 24 Jul 2026
500 mg per caplet; 50 pouches, 2 caplets each
- Product code
- NDC 50580-937-50
- Form and route
- film-coated caplet · oral
- Container
- carton of individual caplet pouches
- Units in each inner container
- 2 caplets per pouchPackage identity only; not an individual amount to take
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-19; actual marketing, stock and availability are not established.
- acetaminophen
- 500 mglabelled amount per tablet/caplet; not an individual's tablet count
- Package
- 50 pouches per carton
- Labelled appearance
- white with red print · 19 mm oval caplet · imprint TYLENOL;500Unscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
TYLENOL Extra Strength label reading: first check 500 mg per caplet and duplicate ingredients
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module only helps check the exact product, ingredient per caplet, package structure and Drug Facts warnings; it provides no personal tablet count, interval, schedule, maximum amount, missed-use action or conversion.
- Check whether other prescription or OTC medicines also contain acetaminophen; different brand names do not rule out a duplicate ingredient. If uncertain, take every pack and the complete medicine list to a pharmacist or clinician.
- The label's 4,000 mg in 24 hours is a severe liver-damage warning boundary, not a target, personal-limit calculator or web regimen. Liver disease, three or more alcoholic drinks daily, warfarin and related situations require clinician or pharmacist review.
- The label's age grouping cannot be turned into an individual child dose. For children under 12, pregnancy or breastfeeding, or persistent or worsening symptoms, use the exact label and contact a clinician or pharmacist.
- For suspected overdose, seek medical help or local poison-control/emergency support immediately even without symptoms; a webpage cannot calculate how much more could be taken.
- The current Drug Facts provides no general missed-use rule; this page does not invent a catch-up, double-use or timing instruction. This displayed caplet is unscored, and the label does not authorise a webpage to decide splitting, crushing or grinding.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. TYLENOL Extra Strength public label (Kenvue; SPL v16) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Tylenol Extra Strength (acetaminophen). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Tylenol Extra Strength is the brand in this record and acetaminophen is the active-ingredient name. Check both with the dosage form (Oral film-coated caplets: acetaminophen 500 mg per caplet; this dossier displays exact package NDC 50580-937-50) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check the exact dosage form
Verify the exact dosage form and current label before altering, transferring or substituting any product. A similar name or previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When COUMADIN / warfarin is on the same list: an analgesic or fever medicine also needs review first
The U.S. public Drug Facts for TYLENOL Extra Strength says to ask a doctor or pharmacist before use when taking warfarin. This card only signals that the actual TYLENOL pack, warfarin pack, other pain/cold products, prescription medicines, OTC products and supplements need review by the responsible team; it does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Coumadin / warfarin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20HOW IT WORKS · NOT A TREATMENT PLAN
Acetaminophen action context: a public label does not replace individual assessment
- A shared use or ingredient name does not make different strengths, extended-release forms, children's liquids, combination cold products or PM products self-interchangeable.
- The 500 mg on the package identifies ingredient amount per caplet; it is not a formula for deriving a personal tablet count from weight, symptoms or other medicines.
- For an acute serious concern, allergy, severe skin reaction or suspected overdose, use local medical and emergency support rather than wait for a web plan.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. TYLENOL Extra Strength public label (Kenvue; SPL v16) ↗reviewed 2026-08-20
- FDA: OTC Monograph M013 Final Administrative Order OTC000027 ↗reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Tylenol Extra Strengthacetaminophen
This page includes an exact current U.S. public-label package panel for Tylenol Extra Strength, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Current DailyMed SPL v16 became effective
This dossier records the exact NDC, 500 mg per caplet and the 50-pouch × 2-caplet package separately. OTC monograph and NDC listing do not mean FDA approval.
DailyMed: current TYLENOL Extra Strength public label, SPL v16 ↗DailyMed published current v16
Publication date remains separate from label effective date; the current package image is bound only to NDC 50580-937-50.
DailyMed: current TYLENOL Extra Strength public label, SPL v16 ↗FDA M013 final administrative order source
FDA OTC000027 is a primary regulatory source for the M013 internal-analgesic monograph; this pathway remains distinct from an approved drug application.
FDA: OTC Monograph M013 Final Administrative Order OTC000027 ↗
MARKET SCOPE
Market-record boundary
United States
Current OTC monograph label and exact package linkedSPL v16 and NDC 50580-937-50 were reviewed through 19 Aug 2026; this does not establish FDA approval, actual marketing, stock or availability.
Mainland China and other markets
Market record not establishedNo local brand, approval, package, supply or interchangeability is inferred from the U.S. label.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Does two caplets per pouch mean two caplets per use?
No. It is package identity only. This page provides no personal tablet count, interval or maximum; use the exact label in hand and ask a pharmacist or clinician.
Can a missed use be made up or doubled?
The current Drug Facts provides no general missed-use rule, so this page does not invent a catch-up or doubling instruction.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.